Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees

Heidi Barth, Jolanta Rybczynska, Romuald Patient, Youkyung Choi, Ronda K. Sapp, Thomas F. Baumert, Kris Krawczynski, T. Jake Liang – 14 June 2011 – Understanding the immunological correlates associated with protective immunity following hepatitis C virus (HCV) reexposure is a prerequisite for the design of effective HCV vaccines and immunotherapeutics. In this study we performed a comprehensive analysis of innate and adaptive immunity following HCV reexposure of two chimpanzees that had previously recovered from HCV‐JFH1 infection.

Efficient production of Fah‐null heterozygote pigs by chimeric adeno‐associated virus‐mediated gene knockout and somatic cell nuclear transfer

Raymond D. Hickey, Joseph B. Lillegard, James E. Fisher, Travis J. McKenzie, Sean E. Hofherr, Milton J. Finegold, Scott L. Nyberg, Markus Grompe – 14 June 2011 – Hereditary tyrosinemia type I (HT1) results in hepatic failure, cirrhosis, and hepatocellular carcinoma (HCC) early in childhood and is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase (FAH). In a novel approach we used the chimeric adeno‐associated virus DJ serotype (AAV‐DJ) and homologous recombination to target and disrupt the porcine Fah gene.

Does adiponectin benefit steatotic liver transplantation?

Maria Elias‐Miro, Marta Massip‐Salcedo, Monica Jimenez‐Castro, Carmen Peralta – 10 June 2011 – Strategies for improving the viability of steatotic donor livers could increase the number of organs suitable for transplantation. There is evidence that adiponectin, the most abundant adipose‐specific adipokine, acts as an anti‐obesity and anti‐inflammatory hormone. Here we review the signaling pathways of adiponectin and the possible therapies based on adiponectin regulation that have been examined or applied clinically.

Cyclic adenosine 3′,5′‐monophosphate in rat steatotic liver transplantation

Monica B. Jimenez‐Castro, Arani Casillas‐Ramirez, Marta Massip‐Salcedo, Maria Elias‐Miro, Anna Serafin, Antoni Rimola, Juan Rodes, Carmen Peralta – 10 June 2011 – Numerous steatotic livers are discarded as unsuitable for transplantation (TR) because of their poor tolerance of ischemia/reperfusion (I/R). Cyclic adenosine 3′,5′‐monophosphate (cAMP)–elevating agents protect against I/R injury both in nonsteatotic livers that have been removed from non–heart‐beating donors and subjected to warm ischemia or cold ischemia (CIS) and in perfused, isolated livers.

Patients' expectations and success criteria for liver transplantation

James R. Rodrigue, Douglas W. Hanto, Michael P. Curry – 7 June 2011 – Patient‐reported outcomes are important to consider when the relative success of liver transplantation (LT) is being evaluated. Our primary objective was to examine the expectations for LT and the criteria for its success across 4 domains of functioning (pain, fatigue, emotional distress, and interference with daily activities) from the perspective of patients who were wait‐listed for LT.

Subscribe to